Switch theme
Sign up to access all valuation multiples
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.
2009
3
LTM Revenue n/a
LTM EBITDA n/a
$1.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stem Cells Spin has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Stem Cells Spin achieved revenue of $14K and an EBITDA of $0.3M.
Stem Cells Spin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stem Cells Spin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $14K | XXX | XXX | XXX |
| Gross Profit | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Margin | 54% | 690% | XXX | XXX | XXX |
| EBITDA | $0.2M | $0.3M | XXX | XXX | XXX |
| EBITDA Margin | 222% | 1808% | XXX | XXX | XXX |
| Net Profit | $7K | -$40K | XXX | XXX | XXX |
| Net Margin | 6% | -284% | XXX | XXX | XXX |
| Net Debt | $0.1M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 20, 2025, Stem Cells Spin's stock price is PLN 0 (or $0).
Stem Cells Spin has current market cap of PLN 6.2M (or $1.6M), and EV of PLN 6.3M (or $1.7M).
See Stem Cells Spin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7M | $1.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 20, 2025, Stem Cells Spin has market cap of $1.6M and EV of $1.7M.
Stem Cells Spin's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Stem Cells Spin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Stem Cells Spin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7M | XXX | XXX | XXX |
| EV/Revenue | 116.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | XXX | XXX |
| P/E | -12.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 145.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStem Cells Spin's NTM/LTM revenue growth is n/a
Stem Cells Spin's revenue per employee for the last fiscal year averaged $5K, while opex per employee averaged n/a for the same period.
Over next 12 months, Stem Cells Spin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Stem Cells Spin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Stem Cells Spin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -87% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $5K | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stem Cells Spin acquired XXX companies to date.
Last acquisition by Stem Cells Spin was XXXXXXXX, XXXXX XXXXX XXXXXX . Stem Cells Spin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stem Cells Spin founded? | Stem Cells Spin was founded in 2009. |
| Where is Stem Cells Spin headquartered? | Stem Cells Spin is headquartered in Poland. |
| How many employees does Stem Cells Spin have? | As of today, Stem Cells Spin has 3 employees. |
| Is Stem Cells Spin publicy listed? | Yes, Stem Cells Spin is a public company listed on WAR. |
| What is the stock symbol of Stem Cells Spin? | Stem Cells Spin trades under SCS ticker. |
| When did Stem Cells Spin go public? | Stem Cells Spin went public in 2011. |
| Who are competitors of Stem Cells Spin? | Similar companies to Stem Cells Spin include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Stem Cells Spin? | Stem Cells Spin's current market cap is $1.6M |
| What is the current revenue growth of Stem Cells Spin? | Stem Cells Spin revenue growth between 2023 and 2024 was -87%. |
| Is Stem Cells Spin profitable? | Yes, Stem Cells Spin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
